A clinical study using Her2-targeting CAR T cells drastically demonstrated the necessity to increase safety of CAR T cell therapies, as already low levels of target antigen expression on healthy tissue led to on-target/off-tumor toxicity causing lethal adverse effects (7). Here, ERBB2 is linked to neoplasm.